Chronic Kidney Disease Progression in Chronic Hepatitis B Patients on Tenofovir Alafenamide (TAF) Versus Entecavir

Active, not recruitingOBSERVATIONAL

Enrollment

1,800

Participants

Timeline

Start Date

September 1, 2022

Primary Completion Date

December 21, 2025

Study Completion Date

December 31, 2026

Conditions

Chronic Hepatitis B

Interventions

DRUG

Tenofovir alafenamide

Chronic hepatitis B patients who are receiving TAF as antiviral therapy for CHB, who were previously treatment naïve.

DRUG

Entecavir

Chronic hepatitis B patients who are receiving ETV as antiviral therapy for CHB, who were previously treatment naïve.

Trial Locations (1)

Prince of Wales Hospital, Shatin

All Listed Sponsors

lead

Chinese University of Hong Kong

OTHER